Grünenthal prohibited the research and manufacture of penicillin by German companies. When the ban was lifted, Grünenthal was the first company to introduce penicillin in the postwar period into the German market. This investment achieved a big financial boost for the company. Chemie Grünenthal synthesized thalidomide in 1954 and acquired a 20-year patent. Soon after obtaining a patent in April 1954, the company started clinical trials, and as early as November 1956, marketed the drug for the treatment of respiratory infections under the trade name Grippex, a combination drug that contained thalidomide, quinine, vitamin C, phenacetin, and acetylsalicylic acid. Researchers at
Tetrahydrocannabinolic acid synthase Tetrahydrocannabinolic acid synthase Tetrahydrocannabinolic acid (THCA) synthase (full name "Δ-tetrahydrocannabinolic acid synthase") is an enzyme responsible for catalyzing the formation of THCA from cannabigerolic acid (CBGA). THCA is the direct precursor of tetrahydrocannabinol (THC), the principal psychoactive component of cannabis, which is produced from various strains of "Cannibis sativa". Therefore, THCA synthase is considered to be a key enzyme controlling cannabis psychoactivity. Polymorphisms of THCA synthase result in varying levels of THC in Cannabis plants, resulting in "drug-type" and "fiber-type" "C. sativa" varieties. THCA synthase is a 60 kDa (~500 amino acids) monomeric enzyme with the isoelectric point at 6.4.